FAQ on HeartBeam Inc.'s New Patents for 3D ECG and Cardiac Monitoring Technology

What are the new patents secured by HeartBeam Inc.?

HeartBeam Inc. has secured two new U.S. patents that protect the core technologies behind its compact, cable-free 3D ECG device and its rhythm analysis algorithm capable of identifying arrhythmias through continuous signal input.

How does the 3D ECG device work?

The 3D ECG device uses chest and finger electrodes to collect high-fidelity signals in three non-coplanar directions, designed for on-demand symptom recording and 12-lead ECG synthesis, with its software currently under FDA review.

What is the significance of these patents for HeartBeam Inc.?

These patents strengthen HeartBeam’s intellectual property portfolio, support its expansion in remote cardiac diagnostics, and solidify its position at the forefront of digital cardiac care innovation.

What future plans does HeartBeam Inc. have for its technology?

HeartBeam plans to incorporate AI capabilities into its technology for enhanced diagnostic accuracy, continuing to innovate in the field of digital cardiac care.

Where can I find more information about HeartBeam Inc.?

For more information about HeartBeam Inc., visit their website at www.HeartBeam.com or the company’s newsroom at https://ibn.fm/BEAT.

How many patents does HeartBeam Inc. currently hold?

HeartBeam Inc. holds 20 issued patents and has 34 additional filings, including 13 U.S. and 4 international-issued patents related to technology enablement.

What is the purpose of HeartBeam’s rhythm analysis algorithm?

The rhythm analysis algorithm works across cardiac monitoring systems to trigger targeted data collection during abnormal rhythm detection, enhancing diagnostic precision.

What is the VALID-ECG pivotal study?

The VALID-ECG pivotal study is the research backing HeartBeam’s software, which is currently under FDA review, supporting the efficacy of its 3D ECG device and rhythm analysis algorithm.